Katherine Lord, Diva D. De León
8 min
All neonates experience a period of metabolic adjustment known as transitional hypoglycemia, where plasma glucose levels naturally drop shortly after birth before rising to adult-like ranges within 72 to 96 hours. This transition is typically driven by the fetal beta cells' persistence of a lower threshold for insulin release. While usually benign, these low glucose levels make it difficult to distinguish healthy transitions from persistent, pathologic hypoglycemic disorders. Because the developing brain relies on glucose and struggles to generate ketones, failure to identify persistent hypoglycemia can lead to irreversible neurocognitive damage.
Clinicians often struggle with the ambiguity of current definitions. There is no universally agreed-upon single glucose threshold for defining hypoglycemia, and many neonates remain asymptomatic even at critically low levels. Relying on symptoms to trigger an evaluation is an unreliable strategy. Instead, the authors advocate for a systematic approach: screening neonates at high risk (e.g., infants of diabetic mothers, those with perinatal stress, or those large for gestational age) and completing a formal evaluation before hospital discharge if the infant fails to maintain stable, normal glucose levels beyond the transitional window.
Hyperinsulinism (HI) is the most common cause of persistent hypoglycemia. Managing it effectively depends on classifying the disorder correctly:
Distinguishing between the focal and diffuse forms of congenital HI is critical. Infants with focal HI can be cured through precise surgical resection guided by 18F-DOPA PET imaging. For those with diffuse forms, management focuses on medical therapy and continuous enteral nutrition to avoid the metabolic and neurodevelopmental risks associated with severe, recurrent hypoglycemia.
After birth, healthy neonates undergo a period of altered glucose metabolism, known as "transitional hypoglycemia." During the first 0 to 4 hours of life, the mean plasma glucose concentration decreases to 57 mg/dL, then by 72 to 96 hours of life increases to 82 mg/dL, well within the normal adult range. Recent data suggest that transitional hypoglycemia is due to persistence of the fetal beta cell's lower threshold for insulin release, resulting in a transient hyperinsulinemic state. While hypoglycemia is an expected part of the transition to postnatal life, it makes the identification of infants with persistent hypoglycemia disorders challenging. Given the risk of neurologic injury from hypoglycemia, identifying these infants is critical. Hyperinsulinism is the most common cause of persistent hypoglycemia in neonates and infants and carries a high risk of neurocognitive dysfunction given the severity of the hypoglycemia and the inability to generate ketones, a critical alternative cerebral fuel. Screening neonates at risk for persistent hypoglycemia disorders and completing evaluations prior to hospital discharge is essential to prevent delayed diagnoses and neurologic damage.
Sam: That explains the danger, but how does it become a diagnostic method? What would clinicians collect beyond another glucose reading?
Alex: The authors call it a critical sample: blood collected during low glucose to identify its cause. It measures metabolic fuels and hormones together. Ideally, it’s collected when plasma glucose is below fifty milligrams per deciliter, either during a spontaneous episode or a supervised diagnostic fast.
Sam: And timing matters here, because the normal transition itself can look like excess insulin action.
Alex: Yes. The authors recommend doing this evaluation after the transitional period, so the results can reflect an underlying disorder. After collecting the sample, clinicians also assess the glucose response to glucagon, a hormone that promotes glucose release from the liver.
Sam: Walk us through the case where that combination changed treatment. What did the measurements show that glucose alone couldn’t?
Alex: A full-term boy was difficult to arouse just before planned discharge. Testing revealed severe low glucose, and he needed substantial intravenous glucose support. During a later low-glucose episode, his ketones and free fatty acids, another circulating fuel source, were suppressed. His glucose rose strongly after glucagon.
Sam: So the pattern pointed to insulin action. Did measuring insulin itself provide the decisive answer?
Alex: The guide explicitly warns against demanding a high insulin result. Assays have limitations, and detectable insulin isn’t required for the diagnosis. Suppressed alternative fuels and the glucagon response are crucial evidence. The pattern matters more than one hormone measurement.
Sam: Once they identified excess insulin action, was medication enough for this infant?
Alex: He received diazoxide, a medicine that suppresses insulin release, but remained dependent on intravenous glucose. Genetic testing then identified a paternally inherited variant associated with focal hyperinsulinism: a localized patch of abnormal insulin-producing cells. Specialized pancreatic imaging located the lesion, and surgeons removed it.
Sam: A localized lesion sounds more treatable than a problem throughout the pancreas. How did they establish that removing it had worked?
Alex: They performed a supervised fast after recovery. He maintained glucose for longer, produced ketones robustly, and no longer showed the abnormal glucose response to glucagon. He went home without therapy. It’s an illustrative case, not a comparative trial, but it makes the diagnostic chain concrete.
Sam: The treatment decision depended on distinguishing focal disease from disease spread throughout the pancreas. How strong is the broader evidence for that distinction?
Alex: The guide reports that experienced teams cure ninety-seven percent of infants with focal disease through surgery. For diffuse disease, involving the pancreas more broadly, surgery is palliative rather than curative. That’s why fully testing medication response and obtaining targeted genetic results are consequential, not optional refinements.
Sam: If the focal form is potentially curable, are these infants generally being identified before they leave the birth hospital?
Alex: The review reports that half are diagnosed only after discharge. That’s the practical gap the authors want to close. For newborns with continuing low glucose beyond the early transition, they recommend further testing rather than assuming frequent feeds have solved the problem.
Sam: We’ve concentrated on excess insulin. Could the same biochemical pattern point somewhere else and send clinicians down the wrong path?
Alex: In newborns, deficient pituitary hormones can resemble hyperinsulinism, including suppressed alternative fuels. The guide therefore emphasizes evaluating hormone production. It also warns that low cortisol or growth hormone in a critical sample does not establish a deficiency. Appropriate stimulation testing is needed before treatment.
Sam: So the sample organizes the differential diagnosis; it doesn’t make every individual result definitive. That seems especially important when translating this guide into a research protocol.
Alex: And the evidence has boundaries. This is a clinical synthesis, not a trial testing the whole care pathway. The excerpt doesn’t give sample sizes or comparison details for several headline estimates. It also says rigorous trials linking neonatal glucose thresholds to later developmental outcomes are lacking.
Sam: Does that uncertainty extend to whether persistent disorders cause lasting harm, or mainly to where a universal glucose boundary should sit?
Alex: The authors describe stronger evidence for neurologic injury in persistent disorders. Studies of hyperinsulinism report neurocognitive deficits in roughly a quarter to nearly half of affected individuals. But that range is not a risk estimate for every baby with an early low reading, nor does it define a universal injury threshold.
Sam: Given that distinction, who should read the full guide, and where should they start?
Alex: Neonatal clinicians, pediatric endocrinologists, and researchers studying newborn glucose regulation should read it closely. Start with Evaluating a Neonate With Hypoglycemia and Interpreting the Critical Sample. Then read the hyperinsulinism management discussion, especially how treatment response guides genetic testing and the search for surgically curable disease.
Sam: And for listeners who won’t be using the diagnostic pathway themselves, what should survive the details?
Alex: Low glucose is a signal, not a diagnosis. In a newborn, ask whether the low glucose is resolving, whether alternative fuels are available, and whether the cause has been established before discharge.
Sam: Thanks for listening.